Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

11. März 2015 09:00 ET | Quelle: Lipocine Inc.

Lipocine Announces Financial and Operational Results for the Full Year 2014

SALT LAKE CITY, March 11, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced financial results for the full year ended December 31, 2014, as well...
04. März 2015 09:00 ET | Quelle: Lipocine Inc.

Lipocine to Present at the 27th Annual ROTH Conference

SALT LAKE CITY, March 4, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice...
27. Februar 2015 09:00 ET | Quelle: Lipocine Inc.

Lipocine Announces Presentation of LPCN 1021 Clinical Data at ENDO 2015

SALT LAKE CITY, Feb. 27, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that data from its ongoing Study of Oral Androgen Replacement...
24. Februar 2015 16:00 ET | Quelle: Lipocine Inc.

Lipocine to Present at the Cowen and Company 35th Annual Health Care Conference

SALT LAKE CITY, Feb. 24, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and Chief Executive Officer, and...
30. Januar 2015 09:00 ET | Quelle: Lipocine Inc.

Lipocine Announces Presentation of LPCN 1107 Clinical Data at the Society for Maternal-Fetal Medicine 35th Annual Meeting

SALT LAKE CITY, Jan. 30, 2015 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that data from a successful Phase 1 study of LPCN 1107, the company's...
12. Januar 2015 09:00 ET | Quelle: Lipocine Inc.

Lipocine Announces Positive Phase 1b Top-Line Results With LPCN 1107 in Pregnant Women

First demonstration of relevant hydroxyprogesterone caproate levels following oral administration in pregnant women Projected dose between 400 and 800 mg twice a day is expected to be...
15. Dezember 2014 08:30 ET | Quelle: Lipocine Inc.

FDA Confirms Lipocine's Previously-Agreed Clinical Development Plan for LPCN 1021

SALT LAKE CITY, Dec. 15, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced that it has received confirmation from the U.S. Food and Drug...
25. November 2014 08:00 ET | Quelle: Lipocine Inc.

Lipocine to Present at the Piper Jaffray 26th Annual Healthcare Conference

SALT LAKE CITY, Nov. 25, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc.(Nasdaq:LPCN), a specialty pharmaceutical company, today announced Mahesh Patel, President and CEO, and Morgan Brown, Executive Vice...
17. November 2014 08:00 ET | Quelle: Lipocine Inc.

Lipocine Announces Management Changes

SALT LAKE CITY, Nov. 17, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced changes to its executive management team. Changes include the...
10. November 2014 08:00 ET | Quelle: Lipocine Inc.

Lipocine Announces Financial and Operational Results for the Third Quarter of 2014

SALT LAKE CITY, Nov. 10, 2014 (GLOBE NEWSWIRE) -- Lipocine Inc. (Nasdaq:LPCN), a specialty pharmaceutical company, today announced financial results for the quarter ended September 30, 2014, as well...

Vorherige Seite

Nächste Seite